Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review-Reference-Cited by-同舟云学术

Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review

Published:2017-06 Issue:6 Volume:43 Page:1003-1012
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology (EJSO)
language:en
Short-container-title:European Journal of Surgical Oncology (EJSO)

Author:

Okuno M.,Hatano E.,Nishino H.,Seo S.,Taura K.,Uemoto S.

Publisher

Elsevier BV

Subject

Oncology,General Medicine,Surgery

Reference45 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer;Leporrier;Br J Surg,2006

3. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer analysis of 1001 consecutive cases;Fong;Ann Surg,1999

4. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline;Desch;J Clin Oncol,2005

5. A retrospective study of the natural history of patients with liver metastases from colorectal cancer;Wood;Clin Oncol,1976

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma;Anticancer Research;2024-03-27

2. Locally advanced mid/low rectal cancer with synchronous resectable liver metastases: systematic review of the available strategies and outcome;Updates in Surgery;2024-01-05

3. Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma;2023-10-30

4. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab;BMC Cancer;2023-08-21

5. Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.;2023-02-06